The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

NCT05913817 · clinicaltrials.gov ↗

COMPLETED

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
Hidradenitis Suppurativa

Interventions

BIOLOGICAL: AVT02 (Alvotech Biosimilar to Adalimumab)

Sponsor

Jamp Pharma Corporation